Haemostatic activation in HIV infected patients treated with different antiretroviral regimens

Angelo Pan, Sophie Testa, Eugenia Quiros Roldan, Carmine Tinelli, Umberto Bodini, Barbara Cadeo, Giusepe Carnevale, Ida Martinelli, Renato Maserati, Pietro Morstabilini, Elena Seminari, Liana Signorini, Giampiero Carosi

Research output: Contribution to journalArticlepeer-review


HIV infected patients treated with highly active antiretroviral therapy (HAART) may be at increased risk of cardiovascular events, particularly if based upon the use of protease inhibitors (PI). We investigated the haemostatic markers of cardiovascular risk in 115 HIV infected subjects, divided into four groups: 1) patie~ts naïve to antiretroviral therapy (Naïve; n=34 patients), or subjects that had been on a stable combination therapy for ≥12 months with either: 2) double reverse transcriptase nucleoside analogue inhibitors therapy (2NRTI; n=26), 3) 2NRTI backbone plus a non-nucleoside analogue reverse transcriptase inhibitor (NNRTI; n=27), and 4) on a PI based regimen (PI; n=28). Forty-faur healthy subjects were included as control. Naïve as well as 2NRTI and NNRTI differed from controls for higher FI+2 (P

Original languageEnglish
Pages (from-to)70-76
Number of pages7
JournalCurrent HIV Research
Issue number1
Publication statusPublished - Jan 2008


  • Antiretroviral therapy
  • Cardiovascular risk
  • Haemostatic marker
  • HIV

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Haemostatic activation in HIV infected patients treated with different antiretroviral regimens'. Together they form a unique fingerprint.

Cite this